Multiparameter cellular and humoral immunoprofiling to differentiate progressive from nonprogressive non-tuberculous mycobacterial lung disease (NTM-LD)

Abstract Background: Biomarkers that predict the patients most likely to develop progressive NTM-LD are urgently needed. We hypothesize flow cytometric (FC) detection of T cell markers after ex vivo antigen challenge in PBMC can differentiate with vs. nonprogressive NTM-LD. also measured serum anti-glycopeptidolipid core IgA antibody by commercial ELISA kit and compared FC immunoprofiling results. Methods: PBMCs were isolated from stimulated purified protein derivative (PPD), mycobacteria-specific peptide pools (MTB300, RD1-peptides). have performed T-cell phenotypic assays measure diagnostic accuracy these ROC non-parametric statistics analysis. Results: A total 29 studied classified into 15 non-progressive 14 based on radiological clinical evaluation. Patients showed a statistically significantly higher frequency PPD-specific CD3 +/CD8 +IFN-γ +HLA-DR +subsets high non-progressors: Sensitivity = 80% specificity 71.4% 0.72. There no other significant differences antigen-stimulated subsets but trend was observed HLA-DR +TNF-α +, CD25 +CD134 +and +PDL1 +T-cell progressors. The anti-GPL levels did not show difference might be useful distinguishing Conclusion: Our study findings suggest CD8 +can distinguish patients, which identify those at risk disease progression.